Gem-TIP in relapsed germ-cell cancer
Can gemcitabine be added to TIP without reducing TIP dose intensity in first-relapse germ-cell cancer?
Phase I/II mixed-GCT cohort (includes seminoma and NSGCT)
Study population as reported in the cited publication; cohort sizes and denominators are stated where available.
Not all evidence is randomized, comparative, or seminoma-specific.
Reported outcomes
In the expanded Gem-TIP cohort, the overall complete response rate was 50%, with a further 30% partial response. One-year failure-free survival was 68% and OS 89.5%; toxicity was predominantly hematologic.
Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.
Interpretation and limitations
Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.
Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025
Primary study source
Salvage chemotherapy with gemcitabine, paclitaxel, ifosfamide, and cisplatin for relapsed germ cell cancer. 2018.
Original study / PubMed / registry ↗
Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.